Skip to main content
NCD 190.32 · version 1 · Laboratory NCD

NCD 190.32: Gamma Glutamyl Transferase

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.32

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
3,933 covered ICD-10
233 non-covered

TL;DR

NCD 190.32 sets Medicare's national policy for gamma glutamyl transferase under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. • To provide information about known or suspected hepatobiliary disease, for example: As a laboratory NCD it carries a national ICD-10 edit list: 3,933 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

Gamma Glutamyl Transferase (GGT) is an intracellular enzyme that appears in blood following leakage from cells. Renal tubules, liver, and pancreas contain high amounts, although the measurement of GGT in serum is almost always used for assessment of hepatobiliary function. Unlike other enzymes which are found in heart, skeletal muscle, and intestinal mucosa as well as liver, the appearance of an elevated level of GGT in serum is almost always the result of liver disease or injury. It is specifically useful to differentiate elevated alkaline phosphatase levels when the source of the alkaline phosphatase increase (bone, liver, or placenta) is unclear. The combination of high alkaline phosphatase and a normal GGT does not, however, rule out liver disease completely.

As well as being a very specific marker of hepatobiliary function, GGT is also a very sensitive marker for hepatocellular damage. Abnormal concentrations typically appear before elevations of other liver enzymes or bilirubin are evident. Obstruction of the biliary tract, viral infection (e.g., hepatitis, mononucleosis), metastatic cancer, exposure to hepatotoxins (e.g., organic solvents, drugs, alcohol), and use of drugs that induce microsomal enzymes in the liver (e.g., cimetidine, barbiturates, phenytoin, and carbamazepine) all can cause a moderate to marked increase in GGT serum concentration. In addition, some drugs can cause or exacerbate liver dysfunction (e.g., atorvastatin, troglitazone, and others as noted in FDA Contraindications and Warnings.)

GGT is useful for diagnosis of liver disease or injury, exclusion of hepatobiliary involvement related to other diseases, and patient management during the resolution of existing disease or following injury.

Indications and limitations of coverage

Indications

• To provide information about known or suspected hepatobiliary disease, for example:

• Following chronic alcohol or drug ingestion.

• Following exposure to hepatotoxins.

• When using medication known to have a potential for causing liver toxicity (e.g., following the drug manufacturer's recommendations).

• Following infection (e.g., viral hepatitis and other specific infections such as amoebiasis, tuberculosis, psittacosis, and similar infections).

• To assess liver injury/function following diagnosis of primary or secondary malignant neoplasms.

• To assess liver injury/function in a wide variety of disorders and diseases known to cause liver involvement (e.g., diabetes mellitus, malnutrition, disorders of iron and mineral metabolism, sarcoidosis, amyloidosis, lupus, and hypertension).

• To assess liver function related to gastrointestinal disease.

• To assess liver function related to pancreatic disease.

• To assess liver function in patients subsequent to liver transplantation.

• To differentiate between the different sources of elevated alkaline phosphatase activity.

Limitations

When used to assess liver dysfunction secondary to existing non-hepatobiliary disease with no change in signs, symptoms, or treatment, it is generally not necessary to repeat a GGT determination after a normal result has been obtained unless new indications are present.

If the GGT is the only "liver" enzyme abnormally high, it is generally not necessary to pursue further evaluation for liver disease for this specific indication.

When used to determine if other abnormal enzyme tests reflect liver abnormality rather than other tissue, it generally is not necessary to repeat a GGT more than one time per week.

Because of the extreme sensitivity of GGT as a marker for cytochrome oxidase induction or cell membrane permeability, it is generally not useful in monitoring patients with known liver disease.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.32 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 3,933 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.32
CodeCode set
82977CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $7.20, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.32 edits, October 2026
CodeCLFS amountWith QWPricing
82977$7.20$7.20national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 3,933 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.32 (sample)
ICD-10-CMDescriptionEffective
A02.1Salmonella sepsis2015-10-01
A06.0Acute amebic dysentery2015-10-01
A06.1Chronic intestinal amebiasis2015-10-01
A06.2Amebic nondysenteric colitis2015-10-01
A06.3Ameboma of intestine2015-10-01
A06.4Amebic liver abscess2015-10-01
A06.5Amebic lung abscess2015-10-01
A06.6Amebic brain abscess2015-10-01
A06.7Cutaneous amebiasis2015-10-01
A06.81Amebic cystitis2015-10-01
A06.82Other amebic genitourinary infections2015-10-01
A06.89Other amebic infections2015-10-01
A06.9Amebiasis, unspecified2015-10-01
A17.83Tuberculous neuritis2015-10-01
A17.9Tuberculosis of nervous system, unspecified2015-10-01
A18.31Tuberculous peritonitis2015-10-01
A18.32Tuberculous enteritis2015-10-01
A18.39Retroperitoneal tuberculosis2015-10-01
A18.82Tuberculosis of other endocrine glands2015-10-01
A18.83Tuberculosis of digestive tract organs, not elsewhere classified2015-10-01
A18.84Tuberculosis of heart2015-10-01
A18.89Tuberculosis of other sites2015-10-01
A19.9Miliary tuberculosis, unspecified2015-10-01
A20.0Bubonic plague2015-10-01
A20.1Cellulocutaneous plague2015-10-01
A20.2Pneumonic plague2015-10-01
A20.3Plague meningitis2015-10-01
A20.7Septicemic plague2015-10-01
A20.8Other forms of plague2015-10-01
A20.9Plague, unspecified2015-10-01
A22.7Anthrax sepsis2015-10-01
A26.0Cutaneous erysipeloid2015-10-01
A26.7Erysipelothrix sepsis2015-10-01
A26.8Other forms of erysipeloid2015-10-01
A26.9Erysipeloid, unspecified2015-10-01
A27.0Leptospirosis icterohemorrhagica2015-10-01
A30.1Tuberculoid leprosy2015-10-01
A32.0Cutaneous listeriosis2015-10-01
A32.11Listerial meningitis2015-10-01
A32.12Listerial meningoencephalitis2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.32 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 0 codes added and 4 codes removed against January 2026. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.

ICD-10-CM codes removed from NCD 190.32 in October 2026
ICD-10-CMDescriptionWasWhy
T52.8X1AToxic effect of other organic solvents, accidental (unintentional), initial encountercovereddeleted from ICD-10-CM; replaced by T52.811A, T52.821A, T52.891A
T52.8X2AToxic effect of other organic solvents, intentional self-harm, initial encountercovereddeleted from ICD-10-CM; replaced by T52.812A, T52.822A, T52.892A
T52.8X3AToxic effect of other organic solvents, assault, initial encountercovereddeleted from ICD-10-CM; replaced by T52.813A, T52.823A, T52.893A
T52.8X4AToxic effect of other organic solvents, undetermined, initial encountercovereddeleted from ICD-10-CM; replaced by T52.814A, T52.824A, T52.894A

Codes on this NCD's list by release: October 2025: 4,141 · January 2026: 4,170 · October 2026: 4,166. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.32

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.32

What does NCD 190.32 cover?

• To provide information about known or suspected hepatobiliary disease, for example: The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.32 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.32?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.32?

The October 2026 laboratory NCD edit list contains 3,933 ICD-10-CM codes that support gamma glutamyl transferase (for example A02.1 Salmonella sepsis; A06.0 Acute amebic dysentery; A06.1 Chronic intestinal amebiasis) and 233 codes that deny. The list applies to 82977.

How often does the lab NCD code list for 190.32 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.